The antitumor activity of the fungicide ciclopirox

International Journal of Cancer

Volumn 127, Issue 10, 2010, Pages 2467-2477

  Zhou, Hongyu ^a   Shen, Tao ^a   Luo, Yan ^a   Liu, Lei ^a   Chen, Wenxing ^a   Xu, Baoshan ^a   Han, Xiuzhen ^a   Pang, Jia ^a   Rivera, Chantal A ^a   Huang, Shile ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

apoptosis; cell cycle; cell proliferation; ciclopirox; retinoblastoma protein

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CICLOPIROXOLAMINE; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; PROTEIN BCL 2; PROTEIN BCL XL; RETINOBLASTOMA PROTEIN; SURVIVIN; BCL2L1 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; CDK2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CICLOPIROX; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL X; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CELL CYCLE; CELL GROWTH; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDONES; RETINOBLASTOMA PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78049512724     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25255     Document Type: Article

References (36)

1. Jue SG, Dawson GW, Brogden RN,. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330-41.
2. Bohn M, Kraemer KT,. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43: S57-S69.
3. Dittmar W, Lohaus G,. HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results. Arzneimittelforschung 1973; 23: 670-4.
4. Abrams BB, Hanel H, Hoehler T,. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471-7.
5. Gupta AK,. Ciclopirox: an overview. Int J Dermatol 2001; 40: 305-10.
6. Leem SH, Park JE, Kim IS, Chae JY, Sugino A, Sunwoo Y,. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells 2003; 15: 55-61.
7. Farinelli SE, Greene LA,. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci 1996; 16: 1150-62.
8. Hoffman BD, Hanauske-Abel HM, Flint A, Lalande M,. A new class of reversible cell cycle inhibitors. Cytometry 1991; 12: 26-32.
9. Almeida B, Sampaio-Marques B, Carvalho J, Silva MT, Leao C, Rodrigues F, Ludovico P,. An atypical active cell death process underlies the fungicidal activity of ciclopirox olamine against the yeast Saccharomyces cerevisiae. FEMS Yeast Res 2007; 7: 404-12.
10. Sakai K, Suzuki K, Tanaka S, Koike T,. Up-regulation of cyclin D1 occurs in apoptosis of immature but not mature cerebellar granule neurons in culture. J Neurosci Res 1999; 58: 396-406.
11. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B,. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1805-17.
12. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick J, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009; 114: 3064-73.
13. Alpermann HG, Schutz E,. Studies on the pharmacology and toxicology of ciclopiroxolamine. Arzneimittelforschung 1981; 31: 1328-32.
14. Beevers CS, Li F, Liu L, Huang S,. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006; 119: 757-64.
15. Malumbres M, Barbacid M,. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-66.
16. Vermeulen K, Van Bockstaele DR, Berneman ZN,. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36: 131-49.
17. Burkhart DL, Sage J,. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-82.
18. Sherr CJ, Roberts JM,. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
19. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D,. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
20. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB,. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273: 10618-23.
21. Youle RJ, Strasser A,. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
22. Santamaria D, Ortega S,. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006; 11: 1164-88.
23. Buss JL, Torti FM, Torti SV,. The role of iron chelation in cancer therapy. Curr Med Chem 2003; 10: 1021-34.
24. Yuan J, Lovejoy DB, Richardson DR,. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004; 104: 1450-8.
25. Whitnall M, Howard J, Ponka P, Richardson DR,. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006; 103: 14901-6.
26. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, Shacter EB,. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res 2009; 69: 948-57.
27. Cazzola M, Bergamaschi G, Dezza L, Arosio P,. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990; 75: 1903-19.
28. Trachootham D, Alexandre J, Huang P,. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-91.
29. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB,. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26: 1106-11.
30. Lindqvist A, Rodriguez-Bravo V, Medema RH,. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 2009; 185: 193-202.
31. Polager S, Ginsberg D,. E2F-at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-35.
32. Feng Z, Hu W, Rajagopal G, Levine AJ,. The tumor suppressor p53: cancer and aging. Cell Cycle 2008; 7: 842-7.
33. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM,. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-8.
34. Grandgirard D, Studer E, Monney L, Belser T, Fellay I, Borner C, Michel MR,. Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 1998; 17: 1268-78.
35. Kasibhatla S, Tseng B,. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003; 2: 573-80.
36. Tait SW, Green DR,. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27: 6452-61.